CA2286909A1 - Composes de 4-aminopyrido¬2,3-d|pyrimidine 5,7-disubstitues et leur utilisation comme inhibiteurs de l'adenosine kinase - Google Patents

Composes de 4-aminopyrido¬2,3-d|pyrimidine 5,7-disubstitues et leur utilisation comme inhibiteurs de l'adenosine kinase Download PDF

Info

Publication number
CA2286909A1
CA2286909A1 CA002286909A CA2286909A CA2286909A1 CA 2286909 A1 CA2286909 A1 CA 2286909A1 CA 002286909 A CA002286909 A CA 002286909A CA 2286909 A CA2286909 A CA 2286909A CA 2286909 A1 CA2286909 A1 CA 2286909A1
Authority
CA
Canada
Prior art keywords
amino
pyrido
pyrimidine
bromophenyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286909A
Other languages
English (en)
Inventor
Shripad S. Bhagwat
Anne Laure Grillot
Chih-Hung Lee
Marlon D. Cowart
Jeffrey Mckie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2286909A1 publication Critical patent/CA2286909A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un procédé permettant une inhibition de l'adénosine kinase par administration d'un composé représenté par la formule générale (I). En l'occurrence, R?1¿ et R?2¿ appartiennent indépendamment au groupe des H, alkyle inférieur, C¿1?-C¿6?alcoxyC¿1?-C¿6?alkyle, arylC¿1?-C¿6?alkyle, -C(O)C¿1?-C¿6?alkyle, -C(O)aryle, -C(O)hétérocyclique ou peuvent se réunir avec l'azote par lequel ils sont rattachés pour former un cycle de 5 à 7 segments contenant éventuellement 1 à 2 hétéroatomes additionnels appartenant au groupe des O, N, ou S. R?3¿ appartient au groupe des alkyle inférieur, alcényle inférieur, alkynyle inférieur, cycloalkyle, aryle, arylalkyle, hétéroaryle, groupe hétérocyclique, hétéroarylalkyle ou hétérocycloalkyle, l'hétéroaryle et l'hétéroarylalkyle ou l'hétérocycloalkyle du groupe hétérocyclique étant directement ou indirectement liés par un groupe carbone. R?4¿ appartient au groupe des alkyle inférieur, alcényle inférieur, alkynyle inférieur, cycloalkyle, aryle, arylalkyle, hétéroaryle, hétéroarylalkyle ou hétérocycloalkyle de groupe hétérocyclique. En outre, le pointillé indique qu'une double liaison est éventuellement présente dans la mesure où l'on conserve les valences correctes. L'invention concerne également une composition pharmaceutique comprenant une quantité thérapeutiquement suffisante d'un tel composé associé à un excipient pharmaceutiquement acceptable. L'invention concerne en outre un traitement de l'ischémie cérébrale, de l'épilepsie, de la douleur, de la nociception, de l'inflammation, de la septicémie, dans le cas d'un mammifère nécessitant un tel traitement, lequel traitement consiste en l'administration, au mammifère considéré, d'une quantité thérapeutiquement suffisante d'un tel composé. L'invention concerne enfin un procédé de préparation d'un tel composé et des composés représentés par la formule considérés, R?1¿, R?2¿, R?3¿ et R?4¿ étant définis séparément.
CA002286909A 1997-04-16 1998-04-14 Composes de 4-aminopyrido¬2,3-d|pyrimidine 5,7-disubstitues et leur utilisation comme inhibiteurs de l'adenosine kinase Abandoned CA2286909A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83821697A 1997-04-16 1997-04-16
US08/838,216 1997-04-16
PCT/US1998/007207 WO1998046605A1 (fr) 1997-04-16 1998-04-14 Composes de 4-aminopyrido[2,3-d]pyrimidine 5,7-disubstitues et leur utilisation comme inhibiteurs de l'adenosine kinase

Publications (1)

Publication Number Publication Date
CA2286909A1 true CA2286909A1 (fr) 1998-10-22

Family

ID=25276561

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286909A Abandoned CA2286909A1 (fr) 1997-04-16 1998-04-14 Composes de 4-aminopyrido¬2,3-d|pyrimidine 5,7-disubstitues et leur utilisation comme inhibiteurs de l'adenosine kinase

Country Status (18)

Country Link
EP (1) EP0989986A1 (fr)
JP (1) JP2001520655A (fr)
KR (1) KR20010006509A (fr)
CN (1) CN1252070A (fr)
AR (1) AR012436A1 (fr)
AU (1) AU7108398A (fr)
BG (1) BG103842A (fr)
BR (1) BR9809055A (fr)
CA (1) CA2286909A1 (fr)
CO (1) CO4940446A1 (fr)
HU (1) HUP0001434A3 (fr)
IL (1) IL131618A0 (fr)
NO (1) NO995036L (fr)
PL (1) PL336304A1 (fr)
SK (1) SK141799A3 (fr)
TR (1) TR199902455T2 (fr)
WO (1) WO1998046605A1 (fr)
ZA (1) ZA983177B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023444A1 (fr) * 1998-10-21 2000-04-27 Abbott Laboratories Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
DE60206363T2 (de) 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
CN1627944A (zh) 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
DE10335183A1 (de) * 2003-07-30 2005-02-24 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2007009911A1 (fr) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag Composes pyrido [2, 3-d] pyrimidine-2, 4-diamine utilises comme inhibiteurs de ptp1b
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
EP1979348B1 (fr) * 2005-12-21 2012-01-18 Abbott Laboratories Composes antiviraux
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
WO2010098487A1 (fr) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Composés hétérocycliques condensés contenant de l'azote et leur utilisation en tant qu'inhibiteurs de production de la bêta-amyloïde
EP2903615B1 (fr) 2012-10-05 2021-04-07 Merck Sharp & Dohme Corp. Dérivés de 5-pyridin-3-yl-2,3-dihydro-1h-indole en tant qu'inhibiteurs de aldostérone synthase (cyp11b2) pour le traitement de l'hypertension artérielle
EP3795563B1 (fr) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Analogues d'indoline et leurs utilisations
CN110256420B (zh) * 2019-05-07 2020-04-28 江西中医药大学 四氢吡啶并嘧啶衍生物及其制备方法和用途
CN110283171A (zh) * 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
HUP0001434A3 (en) 2001-01-29
CO4940446A1 (es) 2000-07-24
HUP0001434A2 (hu) 2000-10-28
NO995036D0 (no) 1999-10-15
SK141799A3 (en) 2000-08-14
JP2001520655A (ja) 2001-10-30
WO1998046605A1 (fr) 1998-10-22
ZA983177B (en) 1999-01-22
PL336304A1 (en) 2000-06-19
EP0989986A1 (fr) 2000-04-05
BG103842A (bg) 2000-06-30
CN1252070A (zh) 2000-05-03
IL131618A0 (en) 2001-01-28
TR199902455T2 (xx) 2000-01-21
AU7108398A (en) 1998-11-11
KR20010006509A (ko) 2001-01-26
NO995036L (no) 1999-10-15
BR9809055A (pt) 2000-08-08
AR012436A1 (es) 2000-10-18

Similar Documents

Publication Publication Date Title
JP6248123B2 (ja) 塩誘導性キナーゼ２（ＳＩＫ２）阻害剤としての置換された１Ｈ−ピロロ［２，３−ｂ］ピリジン及び１Ｈ−ピラゾロ［３，４−ｂ］ピリジン誘導体
CN116406271B (zh) 双环类化合物
WO2000023444A1 (fr) Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
AU2010336386B2 (en) Aminopyrimidine kinase inhibitors
KR102460389B1 (ko) Mnk 억제제 및 그와 관련된 방법
CA2286909A1 (fr) Composes de 4-aminopyrido¬2,3-d|pyrimidine 5,7-disubstitues et leur utilisation comme inhibiteurs de l'adenosine kinase
TW202130641A (zh) 可用作shp2抑制劑的含氮雜原子的六元並五元芳環衍生物
JP2021519783A (ja) Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法
JP2018131449A (ja) ホスファチジルイノシトール３−キナーゼのイソインドリノンインヒビター
HU210814A9 (en) Pyrido pyridazinone and pyridazinthione compounds
HUP0203316A2 (hu) Amino-triazolopiridin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP2001884A1 (fr) Désazapurines utiles comme inhibiteurs des kinases janus
SK16972002A3 (sk) Beta-karbolínové deriváty použiteľné ako inhibítory fosfodiesterázy
CA2206080A1 (fr) Analgesiques
CN116782903A (zh) 取代的吡啶酮化合物及应用
CZ44093A3 (en) L-glutamic acid derivative, process for preparing thereof and pharmaceutical preparation in which said derivative is comprised
AU7098198A (en) 6,7-disubstituted-4-aminopyrido(2,3-d)pyrimidine compounds
US6030969A (en) 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
WO1998046604A1 (fr) Composes de 4-aminopyridol[2,3-d]pyrimidine a trisubstitution 5,6,7
CZ339399A3 (cs) 5,7-Disubstituované 4-aminopyrido[2.3- D]pyrimidinové sloučeniny a jejich použití jako inhibitorů adenosin kinasy
KR20230171440A (ko) 약학적 화합물
MXPA99009512A (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds
CZ350899A3 (cs) 5,6,7-trisubstituované-4-aminopyrido-[2,3- D]pyrimidinové sloučeniny
CZ360199A3 (cs) Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu

Legal Events

Date Code Title Description
FZDE Discontinued